Pharmaceutical Industry in the
Canton of Basel-Country

Basilea Pharmaceutica AG, Allschwil

Since 2002 · 101–500 empl.·4.5(2)

Basilea Pharmaceutica AG, Allschwil is a pharmaceutical company that develops and commercializes medicines for severe and life‑threatening bacterial and fungal infections. Its portfolio includes antifungal and antibacterial products such as Cresemba (isavuconazole) and Zevtera.

Novartis Pharma Schweizerhalle AG

Since 1938 · 21–50 empl.

Novartis Pharma Schweizerhalle AG is a Novartis production site for chemical active substances and intermediates. The site carries out complex manufacturing processes, laboratory analysis and release for further processing within the production network.

Dr. Grossmann AG, Pharmaca

Since 1977 · 1–10 empl.

Dr. Grossmann AG, Pharmaca operates a website for a pharmaceutical company. The homepage provides language versions in German, English, French and Spanish.

Merz Pharma (Schweiz) AG

Since 1977 · 51–100 empl.

The core activity of Merz Therapeutics is the development, manufacture and marketing of pharmaceuticals, particularly in the fields of neurology, hepatology and dermatology. The company focuses on researching and developing innovative therapies to improve the quality of life for patients.

CARBOGEN AMCIS AG

Since 1982 · 101–500 empl.

CARBOGEN AMCIS AG is a CDMO providing development and manufacturing services for drug substance (APIs) and drug product. Services include process development, GMP and non-GMP manufacturing, sterile injectable production, cholesterol and vitamin D specialties, and support functions such as quality management, regulatory affairs and project management.

Pharmatrans Sanaq AG

Since 1982 · 11–20 empl.

The core activity of Pharmatrans SANAQ AG is the development, manufacture and distribution of excipients and active ingredients for the pharmaceutical industry. The company offers standardized and customer-specific solutions and supports its customers in the development and production of medicinal products.

Andreabal AG

Since 1988 · 11–20 empl.

The core activity of Andreabal AG is the development, manufacture and distribution of products for women before, during and after pregnancy, including pregnancy preparation, breastfeeding and menopause, as well as vitamins, iron deficiency and skin and nail care products.

Abbott Laboratories GmbH

Since 1989 · 51–100 empl.

Abbott Laboratories GmbH develops and supplies healthcare products and solutions, with a focus on diagnostics, diabetes-care systems, cardiovascular (heart and vascular) therapies and medical nutrition.

Curatis AG

Since 1993 · 21–50 empl.

Curatis AG is a specialty pharmaceutical company focused on acquiring, developing and commercialising medicines for the prevention, diagnosis and treatment of rare and specialty‑care diseases. The company operates a distribution business for third‑party orphan and specialty medicines and a development business advancing proprietary drug candidates (e.g., C‑PTBE‑01, C‑AM‑01, C‑MOH‑01, C‑FI‑01) toward clinical development.

Medius AG

Since 1997 · 1–10 empl.

The core activity of Medius AG is to provide services in the field of regulatory affairs for pharmaceuticals and health products, including market authorization, quality assurance and development. The company particularly supports international companies in their market entry into Switzerland and offers consulting and services in these areas.

Desitin Pharma GmbH

Since 1997 · 11–20 empl.

The core activity of Desitin Pharma GmbH is the development, manufacture and marketing of pharmaceuticals, particularly in the therapeutic area of epilepsy. The company focuses on the galenics of medications and offers innovative dosage forms that facilitate intake and increase compliance.

Actelion Pharmaceuticals Ltd

Since 1997 · 21–50 empl.

Actelion Pharmaceuticals Ltd is a pharmaceutical company focused on the research, development, and marketing of medicines. The website presents Johnson & Johnson Innovative Medicine’s therapeutic areas, including oncology, immunology, neuroscience, and cardiopulmonary care.

ADD Advanced Drug Delivery Technologies Ltd

Since 1998 · 1–10 empl.

The core activity of ingredientpharm is the development and marketing of niche pharmaceutical excipients, particularly for solid dosage forms, with a strong focus on controlled release and taste masking. The company also offers solutions for the development and production of pharmaceutical and cosmetic products, including the supply of active ingredients, excipients and services such as the development of customized formulations and the production of samples.

SynphaBase AG

Since 2000 · 11–20 empl.

The core activity of SynphaBase AG is the development and implementation of processes for the synthesis of complex organic compounds, particularly in the fields of medicinal chemistry, carbohydrate chemistry and process research and development. The company offers services such as laboratory synthesis, synthesis route development, process development and the production of organic and bioactive molecules.

Protzek Biotec GmbH

Since 2003 · 11–20 empl.

The core activity of Protzek is the development, production and distribution of objective test and analysis systems for medical, police and forensic applications, particularly in the fields of toxicology and virology, with a focus on sustainable and environmentally friendly products.

Amacom GmbH

Since 2003 · 1–10 empl.

Amacom GmbH offers selected products and services and provides web offerings such as “Butler Team” and “Terra Natura”. The company website lists contact details including a phone number, email address and a contact form.

Herbonis AG

Since 2004 · 51–100 empl.

Herbonis AG develops and sells natural solutions for animal nutrition. The company offers specialty feed ingredients and products for different animal species, including poultry, ruminants, swine and aquaculture.

Xenometrix AG

Since 2005 · 1–10 empl.

Xenometrix AG supplies bioassay products and related analytical services for mutagenicity, genotoxicity, endocrine activity screening and skin absorption studies. The company produces and distributes standardized test kits (including miniaturized Ames test formats such as Ames II and Ames MPF), XenoScreen endocrine receptor assays, micronucleus and cytotoxicity assays, and offers GLP and non‑GLP service analytics as well as kit components and ex‑vivo skin samples for penetration testing.

Thermo Fisher Diagnostics AG

Since 2006 · 101–500 empl.

Thermo Fisher Diagnostics AG supplies diagnostic instruments, reagents, consumables, software and related services for clinical laboratories and life‑science research. Its portfolio includes laboratory equipment and analytical systems for sample and material characterization, chemical analysis and clinical diagnostics.

Baliopharm AG

Since 2007 · 1–10 empl.

Baliopharm AG is a biotechnology company developing antibody therapeutics for chronic liver diseases, immune-mediated inflammatory diseases and oncology. Its portfolio includes monoclonal antibodies and antibody-derived formats such as monovalent and bispecific constructs designed for targeted selectivity.

EpiPharm AG

Since 2007 · 1–10 empl.

EpiPharm AG is a clinical-stage biotechnology company developing topical treatments and dermato-cosmetic products based on multi-active, plant-derived compositions that include artemisinin derivatives. Its projects address skin disorders such as seborrhoeic keratosis and pigmented lesions, and the company offers co-development and licensing opportunities for its pipeline.

Thermo Fisher Scientific (Schweiz) AG

Since 2008 · 101–500 empl.

Thermo Fisher Scientific (Schweiz) AG supplies scientific instruments, reagents, consumables, software and services for research, diagnostics, biopharma and industrial laboratories. Its portfolio includes laboratory equipment, antibodies and assays, contract development and manufacturing (CDMO/CRO) services, instrument support and lab informatics solutions.

Cederberg GmbH

Since 2008 · 1–10 empl.

Cederberg GmbH is an international healthcare company focused on developing and commercialising patent-protected medicines and medical devices. Its activities include speciality prescription pharmaceuticals and medical devices for areas such as gastroenterology, gynaecology, urology and endocrinology, and commercial products include Moventig®, Tostran®, Rectogesic® and Gynomunal®.

Drug'On Pharma Switzerland AG

Since 2009 · 1–10 empl.

Drug'On Pharma Switzerland AG is part of the Orofino Pharmaceuticals group and operates a chemical production site manufacturing active pharmaceutical ingredients (APIs) and intermediates. The site comprises four production buildings and provides chemical manufacturing capabilities for APIs and intermediates.

Probiocon GmbH

Since 2012 · 1–10 empl.

Probiocon GmbH is a consulting firm offering tailored services to biopharmaceutical and biotechnological companies. Its main areas of activity include corporate development and strategy, as well as technical project and outsourcing management.

Opterion Health AG

Since 2012 · 11–20 empl.

The core activity of Opterion Health AG is the development and marketing of a new, non-glucose-based osmotic agent for peritoneal dialysis (PD) in patients with end-stage renal disease. The company focuses on creating an innovative product that reduces the metabolic side effects of conventional glucose-based solutions and improves the quality of life for patients.

INOFEA AG

Since 2014 · 11–20 empl.

The core activity of INOFEA AG is the development of enzyme-based solutions for the optimized synthesis of high-quality compounds in production processes.

T3 Pharmaceuticals AG

Since 2015 · 11–20 empl.

The core activity of T3 Pharmaceuticals AG is the development of anti-cancer drugs, particularly through the research and development of innovative therapeutics based on microbial pathogenesis and immunotherapy. The company focuses on the discovery and development of new active substances (NCEs) and the clinical development of targeted therapeutics, especially in the fields of oncology and hematology.

DXC RT AG

Since 2015 · 1–10 empl.

The core activity of DXC RT AG is the development and application of biotechnological solutions, particularly the NovaPhyRT technology, for the cultivation of plant roots in laboratories. The company specializes in the production of root biomass, including Hairy Root, Adventitious Root and Callus and cell suspensions, and supplies these products to customers in the cosmetics and care industry. In addition, DXC RT also offers customized research and development services.

Accord Healthcare AG

Since 2016 · 11–20 empl.

The company's core activity is the development, production and distribution of pharmaceuticals, in particular generics, biosimilars and original products, with a focus on the therapeutic areas of oncology, autoimmunity/rheumatology and CNS.

Valerius Biopharma AG

Since 2017 · 1–10 empl.

Valerius Biopharma AG develops biosimilars and manages a portfolio of orphan and non‑orphan candidates, conducting R&D on cell lines, process development and extensive analytical characterization.

saverna therapeutics AG

Since 2017 · 1–10 empl.

The core activity of Saverna Therapeutics is the discovery and development of small, orally active molecules targeting non-coding RNA biology to treat diseases with unmet medical needs. The company utilizes a platform based on artificial intelligence and nuclear magnetic resonance to reduce the time and cost of drug development.

acovos AG

Since 2017 · 1–10 empl.

The core activity of Acovos is to provide high-quality, well-characterized human tissue samples for the pharmaceutical and biotechnology industries. In particular, Acovos offers a comprehensive collection of formalin-fixed, paraffin-embedded (FFPE) tissue samples, including tumor, inflammatory, degenerative and normal tissues, as well as matching tissue pairs and tissue samples tested for specific antibodies. These samples are used for the development of drugs and diagnostic products.

Premark Pharma GmbH

Since 2018 · 21–50 empl.

Premark Pharma GmbH develops and commercialises topical treatments for inflammatory diseases of the skin, eye, mucosae and mucocutaneous surfaces. Its lead ophthalmic assets include pimecrolimus formulations such as PMP2207 (an ointment for blepharitis) and PMP1606 (a liquid suspension for dry eye), with Phase 3 programmes planned and regulatory approvals sought in the EU and US.

Gigabases Switzerland AG

Since 2018 · 1–10 empl.

Gigabases Switzerland AG operates a web-based platform for 3D protein design and ordering sequence-verified expression plasmids. The platform provides a database of over 214 million protein 3D structures, tools to modify proteins at the amino-acid level, and algorithms that translate designs into ready-to-order plasmids for mammalian, viral, or bacterial expression.

CAPTOR THERAPEUTICS GmbH

Since 2018 · 11–20 empl.

The core activity of Captor Therapeutics is the development of medicines, particularly in the early stages of drug development, with a focus on reprogramming proteins to treat previously incurable diseases.

Alloy Therapeutics (Switzerland) AG

Since 2019 · 21–50 empl.

Alloy Therapeutics (Switzerland) AG develops and provides technologies and services for drug discovery and development. Its activities focus on antibodies and multispecifics, TCR mimics, genetic medicines, pharmacology, and AI/ML-enabled platforms.

BioInitials AG

Since 2019 · 11–20 empl.

BioInitials AG develops non-invasive medical devices and a monitoring platform that analyze saliva biomarkers to assess health status, disease risk factors and disease progression. Biomarker data is combined with other inputs and evaluated using artificial intelligence; project work has included sensor units measuring saliva pH, glucose and impedance.